CSPIA
JAZZ icon

Cary Street Partners Investment Advisory’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-76
Closed -$9.84K – 1240
2023
Q3 		$9.84K Hold
76
– – ﹤0.01% 1307
2023
Q2 		$9.42K Buy
76
+15
+25% +$2.02K ﹤0.01% 1255
2023
Q1 		$8.93K Buy
61
+5
+9% +$740 ﹤0.01% 1176
2022
Q4 		$8.92K Buy
+56
New +$8.21K ﹤0.01% 1188

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cary Street Partners Investment Advisory's JAZZ Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2023, closing a stake of 76 shares — an estimated $9.84K sold.

Cary Street Partners Investment Advisory first reported a position in JAZZ in Q4 2022 and held it in 4 quarters. The position peaked at $9.84K in Q3 2023. 500 funds tracked by Wall St. Rank hold JAZZ as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Jazz Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 76 Jazz Pharmaceuticals shares in Q4 2023, an estimated $9.84K.
  • Cary Street Partners Investment Advisory first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Jazz Pharmaceuticals position peaked at $9.84K in Q3 2023.
  • 500 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.